PRESS RELEASE
Uppsala
February 2, 2010
Q-Med AB invites to year-end report 2009 conference call
Time: Friday, February 12 at 10.30 a.m. CET.
To join the conference: Swedish dial in number: +46 8 5052 0114
UK dial in number: +44
207 1620 177
Q-Med participants: Bengt Ågerup, CEO
Alexander Kotsinas, CFO
Q-Med AB's year-end report will be released 8.00 a.m. on February 12, 2010.
The slide presentation will be available at www.q-med.com
<http://www.q-med.com/> and Investors/Presentations.
A recorded version of the presentation will be available for seven working days
on
tel: Sweden +46 8 505 203 33 or UK +44 20 7031 4064, access code: 857246
Financial information from Q-Med during 2010
12 February Year-end Report 2009
23 April Interim Report January - March 2010
28 April Annual General Meeting
22 July Interim Report January - June 2010
22 October Interim Report January - September 2010
Queries should be addressed to:
Camilla Schartau, IR Co-ordinator
Tel: +46 733 87 14 22
Q-Med AB is a medical device company. The company develops, manufactures,
markets, and sells primarily medical implants. The majority of the products are
based on the company's patented technology, NASHA(TM), for the production of
stabilized non-animal hyaluronic acid. The product portfolio today contains:
Restylane® for filling lines and folds, contouring and creating volume in the
face, Macrolane(TM) for body contouring, Durolane(TM) for the treatment of
osteoarthritis of the hip and knee joints, Deflux® for the treatment of
vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children,
and Solesta(TM) for the treatment of fecal incontinence. Sales are made through
the company's own subsidiaries or distributors in over 70 countries. Q‑Med today
has about 650 coworkers, with approximately 400 at the company's head office and
production facility in Uppsala, Sweden.
Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic.
Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail: info@q-med.com
<mailto:info@q-med.com>. Web: www.q-med.com <http://www.q-med.com/>.
[HUG#1379758]
Q-Med year-end report 2009
| Source: Q-Med AB
Attachments
